免疫相关基因Tap2、HLA-DR9与新疆哈萨 克族食管癌的交互作用
A 1:2 Case-control Study of Tap2/HLA-DR9 Gene Polymorphism with Esophageal Cancer in Kazakh
-
摘要: 目的探讨Tap2379、Tap2665基因多态性、HLA-DR9等位基因频率与新疆哈萨克族(简称哈族)食管癌的相关性。 方法采用1∶2配比的病例对照研究,收集哈族食管癌194例,健康对照388例,运用序列特异性引物聚合酶链反应-限制片段长度多态技术(PCR-RFLP)检测Tap2379、Tap2665基因多态性,序列特异性引物聚合酶链反应(PCR)检测HLA-DR9等位基因频率,采用χ2检验、多因素条件Logistic回归进行统计分析。结果病例组与对照组间比较,Tap2379基因型差异有统计学意义(χ2=18.247,P<0.05,OR=2.347 ,95%CI:1.587~3.471);Tap2665基因型差异无统计学意义(χ2=2.175,P>0.05,OR=1.317,95%CI:0.919~1.899);HLA-DR9等位基因频率差异有统计学意义(χ2=13.443,P<0.05,OR=2.343,95%CI:1.486~3.693)。多因素条件Logistic回归示:Tap2379位多态性分布、HLA-DR9等位基因阳性率、食管或胃疾病史在哈萨克族食管癌和健康对照间存在差异。交互作用示:Tap2379位多态性与HLA-DR9等位基因协同作用时可使食管癌的发生危险性增加到5.302倍(95%CI:2.363~11.900)。结论Tap2379位Val(G)→lla(A)转变、HLA-DR9等位基因阳性为哈族食管癌的危险因素,两者对食管癌的发生存在效应修饰作用。Abstract: ObjectiveTo evaluate the association between Tap2379/Tap2665 genetic polymorphisms/ HLA-DR9 immune-associated gene and esophageal cancer (EC) in a high incidence Kazakh of Xinjiang. MethodsA case-control study was conducted with 194 cases of EC and 388 controls. Tap2379/Tap2665 genotypes were detected by PCR-RFLP and HLA-DR9 allele gene were identified by PCR.The conditional logistic regression model was performed in this study. ResultsTap2379 genotype frequencies of esophageal cancer group was different from the controls(χ2=18.247,P<0.05,OR=2.347,95%CI:1.587~3.471);Tap2665 genotype did not find this difference(χ2=2.175,P>0.05,OR=1.317,95%CI:0.919~1.899); HLA-DR9 allele positive of case group was different from the controls(χ2=13.443,P<0.05,OR=2.343,95%CI:1.486~3.693).Multivariate conditional logistic regression analysis showed: Tap2379 genetic polymorphisms/ HLA-DR9 gene and history of esophageal or stomach disease were risk factors of Kazakh esophageal cancer. The interaction analysis showed Tap2379 genetic polymorphisms with HLA-DR9 allele gene significantly increased risk to the development of esophageal cancer 5.302(95%CI:2.363~11.900). Conclusion Tap2379 genetic polymorphisms and HLA-DR9 allele gene are important risk for EC, Tap2665 genotype did not found this action. Tap2379 and HLA-DR9 showed an additive risk to develop esophageal carcinoma.